statistiche ricercatore

Nome	#
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma	127
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?	101
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?	60
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution	58
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System	45
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination	30
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors	12
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication	6
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies	4
Totale	443

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	119	0	0	0	0	34	10	22	6	7	5	6	29
2021/2022	106	2	0	3	4	9	4	3	13	20	5	31	12
2022/2023	137	6	16	8	7	5	8	10	8	29	11	12	17
2023/2024	56	6	6	1	6	2	13	3	4	2	5	8	0
2024/2025	25	25	0	0	0	0	0	0	0	0	0	0	0
Totale													443

CRIS Current Research Information System